Teva Pharmaceutical Industries News

Takeda Pharmaceutical Co., Asia's biggest drugmaker, sued Teva Pharmaceutical Industries Ltd., alleging infringement of a U.S. patent for the insomnia treatment Rozerem.

Is this a rare case of Teva Pharmaceutical being forced to swallow its own bitter medicine? The world's largest generic manufacturer, founded on its unflinching willingness to challenge the patented protection of branded products owned by other drugmakers, is suing generic rival Mylan .

Put players pounced on Teva Pharmaceutical Industries Ltd. on Tuesday, after the drug maker stepped into the earnings spotlight.

Pfizer Inc. is wooing up-and-coming Israeli biotech Protalix Biotherapeutics for a possible buyout or partnership, the financial newspaper TheMarker reported Monday.

Omnicare Inc , the largest U.S. provider of pharmacy services to nursing homes, will pay $98 million and Teva subsidiary IVAX Pharmaceuticals will pay $14 million to settle allegations of kickbacks, the U.S. Department of Justice said on Tuesday.

Expeditors International of Washington, Inc , the transportation company reported third quarter revenues fell 33.3% to $1.04 billion from $1.56 billion a year ago.

Israeli stocks fell on Tuesday, with the benchmark index on the verge of closing below 1000 points for the first time in a month, led by weakness in telecom provider Bezeq, while Teva Pharmaceutical slipped after reporting third-quarter earnings.

Teva Pharmaceutical beat earnings expectations with its third-quarter report, although sales fell short of expectations despite a 25% increase.

Main Category: Stem Cell Research Also Included In: Blood / Hematology ; Conferences Article Date: 03 Nov 2009 - 1:00 PST At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed ...

Usually, confirmatory phase 3 trials don't cause 40% gains in a stock. Especially after the first one resulted in a crazy 500%-plus gain.

These companies are projected to increase revenue and profit by at least 12% in the coming year and have "buy" ratings from our quantitative model, which considers more than 60 factors.

Israeli stocks declined for a fourth session on Sunday, with the benchmark index barely keeping above the 1000-point mark, as investors particularly punished financial and technology stocks.

Technically, Human Genome Sciences has one drug for sale, but it's between shipments of ABthrax, its anthrax treatment, to the government, so Human Genome's earnings release Thursday was rather dry.

Sometimes it's hard to predict how patients and doctors will react to medical news.

Drug stocks edged up in early trading Monday as shares of BioCryst Pharmaceuticals soared on news that U.S. regulators will allow its experimental flu treatment peramivir to be given to hospitalized H1N1 flu victims under certain circumstances.

Mylan Inc. said today that two of its subsidiaries settled a long-standing dispute with the U.S. Justice Department over Medicaid drug rebates.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, generic-drug specialist Teva Pharmaceutical has earned a coveted five-star ranking .

Teva Pharmaceutical Industries Ltd. announced that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase, an enzymatic debriding agent for burns.

Cephalon Inc. said Wednesday it was notified that Teva Pharmaceuticals has filed an application with the Food and Drug Administration seeking approval to market a generic version of Cephalon's Nuvigil.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.